Evidence map›Paper›PMID 37682301›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

The usefulness of [

Peipei Wang, Shuai Liu, Xiaojie Li, Xing Liu, Shaowu Li, Zhen Wu, Xin Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.European journal of nuclear medicine and molecular imaging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Peipei Wang *Department of Nuclear Medicine, Beijing , Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Shuai Liu *Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xiaojie Li *Department of Neurosurgery, Fengtai District, Beijing Tiantan Hospital, Capital Medical University, No. 119, the West Southern 4Th Ring Road, Beijing, 100073, China.
Xing LiuBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Shaowu LiBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Zhen WuDepartment of Neurosurgery, Fengtai District, Beijing Tiantan Hospital, Capital Medical University, No. 119, the West Southern 4Th Ring Road, Beijing, 100073, China. wuzhen1966@aliyun.com.
Xin ChengDepartment of Nuclear Medicine, Beijing , Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China. chengx@pumch.cn.ORCID 0000-0002-7836-8724
Capital Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-070National Natural Science Foundation of China 82001778
6 · The paper itself

Abstract

purposeClinical studies of PET imaging using SSTR2 agonists have demonstrated high accuracy and correlation with SSTR2 expression in meningiomas. However, the usefulness of the SSTR2 antagonist with [ MATERIALS AND

methodsPatients with suspected de novo or recurrent meningioma in complex locations or atypical images were enrolled from August 2021 to October 2022 in prospective study. All patients underwent contrast-enhanced MRI (CE-MRI), [

resultsOf 36 (50.0 ± 13.0 years of age, 20 women) patients, 32 were histopathologically confirmed meningiomas and four with other tumors. [

conclusions[

Indexed as

Meningeal NeoplasmsMeningiomaOrganometallic CompoundsAdultFemaleGallium RadioisotopesHeterocyclic Compounds, 1-RingHumansMagnetic Resonance ImagingNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProspective StudiesYoung Adult1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidGallium RadioisotopesHeterocyclic Compounds, 1-RingOrganometallic Compounds[68 Ga]Ga-DOTA-JR11MeningiomaMRIPET/CT

Identifiers

PMID37682301
OpenAlexW4386529505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.